Suzhou's CStone Pharma (HK: 2616) was approved to start a bridging Phase I/II clinical trial in China of avapritinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST). In June 2018, CStone acquired China rights to avapritinib and two other oral genomic-based potential cancer agents from Blueprint Medicine of the US in a deal worth up to $386 million. The goal of the Phase I/II bridging study is to allow CStone to participate in the global Phase III trial of the candidate. More details....
Share this with colleagues:
Original Article: CStone Approved to Start China Bridging Trial of GIST Candidate